Mark Goldsmith joined Third Rock Ventures in 2012 as a Venture Partner, where he serves as a senior advisor to the firm and participates in the ideation, development and leadership of new companies.
Prior to joining Third Rock, Mark was President and Chief Executive Officer of Constellation Pharmaceuticals, the leading biopharmaceutical company in the field of epigenetics and a Third Rock Ventures portfolio company. Mark continues his active involvement with Constellation Pharmaceuticals by serving as Executive Chairman. Before Constellation, Mark held senior executive positions in the biotechnology industry and academia. Prior to his appointment at Constellation in 2009, Mark was a Senior Executive-in-Residence at Prospect Venture Partners, a leading healthcare venture capital firm. Previously, he served as CEO of Cogentus Pharmaceuticals and as Senior Vice President leading the health care division of Genencor International. Before entering the private sector, Mark led a medical research laboratory at the Gladstone Institute of Virology and Immunology, practiced medicine on the faculty of the University of California, San Francisco School of Medicine and at San Francisco General Hospital, and was a consultant to leading pharmaceutical and biotechnology companies. He received his undergraduate degree from Princeton University, earned his M.D. and Ph.D. in microbiology and immunology from the University of California, San Francisco and conducted postgraduate medical training at Harvard Medical School and the University of California, San Francisco.
Year Joined Third Rock
2012
Current Roles
Executive Chairman of the Board of Directors at Constellation Pharmaceuticals
Charles Homcy joined Third Rock Ventures' in 2010 as a Venture Partner. Charles co-founded Portola Pharmaceuticals in 2003 and served as President and Chief Executive Officer from that time until April 2010.
Prior to that, he was President of Research and Development at Millennium following Millennium's acquisition of COR Therapeutics in 2002. Charles joined COR in 1995 as Executive Vice President of Research and Development, and he served as a Director of the company from 1998 to 2002.
He has been a clinical professor of medicine at the University of California, San Francisco Medical School, and attending physician at the San Francisco VA Hospital since 1997. He was previously President of the medical research division of American Cyanamid-Lederle Laboratories, a division of Wyeth. Charles serves as co-chairman of the board of directors of Portola and is a board member of Geron Corporation. Charles received his AB and MD from Johns Hopkins University.
Steve Paul joined Third Rock Ventures in 2010, and serves as a senior advisor to the firm and participates in the ideation and development of potential new companies. Steve has had a distinguished career in neuroscience, particularly in CNS drug discovery and development.
Steve is the former president of the Lilly Research Laboratories of Eli Lilly and Company and now leads the Helen & Robert Appel Institute for Alzheimer's Research at Weill Cornell Medical College. Prior to his appointment at Weill Cornell, Steve spent 17-years at Eli Lilly, during which time he held several key leadership roles, including vice president of neuroscience (CNS) research and group vice president of discovery research (all therapeutic areas). In his most recent role, he was responsible for the company's overall research and development efforts - helping to expand Lilly's R&D efforts in oncology and biotechnology - resulting in a pipeline of approximately 70 new molecular entities. Prior to Lilly, Steve served as Scientific Director of the National Institute of Mental Health. He has also served as Medical Director in the Commissioned Corps of the United States Public Health Service.
Steve has been the recipient of many awards and honors and has served on numerous committees and advisory boards. He has also authored or co-authored over 500 papers and book chapters. Steve is an elected fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. He is also currently on the board of directors or is a trustee of several organizations, including the Sigma-Aldrich Corporation, Alnylam Pharmaceuticals, the Allen Institute for Brain Sciences, The Mind Research Network, and the Foundation for the NIH. Steve has also served as a member of the National Institute of General Medical Sciences (NIGMS) Advisory Council and was appointed by the secretary of the Department of Health and Human Services (HHS) as a member of the advisory committee to the director of the NIH from 2001-2006. Steve is currently a member of the National Advisory Mental Health Council, NIMH, and is board certified by the American Board of Psychiatry and Neurology. Steve received his Bachelor of Arts degree in Biology and Psychology from Tulane University in 1972, and his Master of Science and Doctor of Medicine degrees from the Tulane University School of Medicine in 1975.
Phil Reilly joined Third Rock Ventures in 2009, and supports the firm’s founding and advancement of new ventures, with a particular focus on seeking to nurture and grow transformational companies dedicated to breakthrough treatments for genetic disorders. Phil is an accomplished entrepreneur, and has a long standing interest in genetic testing and in developing new therapies for genetic diseases.
Phil is currently a trustee of Cornell University and has served twice (2000 & 2003) as President of the American Society of Law, Medicine, and Ethics. He is a founding fellow of the American College of Medical Genetics, the author of six books, and frequently speaks about genetics, the future of medicine, and bioethics. Phil has also held numerous teaching positions at Tufts University School of Medicine, Harvard Medical School, Cornell University and as has served as adjunct professor of both legal studies and biology at Brandeis University.
Phil holds an MD from Yale University, a JD from Columbia University, is a member of the Massachusetts Bar and is board certified in internal medicine and clinical genetics.
Current Roles
Board Member of Lotus Tissue Repair
Board Member of Edimer Pharmaceuticals
Interim CMO and Scientific Advisory Board Member of bluebird bio
Greg Verdine joined Third Rock Ventures in 2009, and provides scientific due diligence for the firm’s potential portfolio investments. Greg is a thought leader in the field of chemical biology and an accomplished drug discovery entrepreneur.
Greg currently serves as the Director of the Chemical Biology Initiative and the Program in Cancer Chemical Biology at the Dana-Farber Cancer Institute, and is the Erving Professor of Chemistry at Harvard University.
Prior to joining Third Rock Ventures, Greg co-founded a number of biotechnology companies in addition to serving as a founding scientific advisor to Vertex Pharmaceuticals and Variagenics, Inc.
Greg holds a PhD in Chemistry from Columbia University, a BS in Chemistry from St. Joseph’s University, and served as a NIH Postdoctoral Fellow in Molecular Biology at MIT and Harvard Medical School. He is currently a Scientific Advisor to the Board of Directors of the Ibusuki Medipolis Research Institute; the Bill and Melinda Gates Foundation; the Board of Scientific Consultants of the Memorial Sloan-Kettering Research Institute; and the Scientific Advisory Board of the SMA Foundation.
Current Roles
Interim Chief Scientific Officer, Chairman and Scientific Advisory Board Member of Warp Drive Bio
